These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25360866)

  • 1. Preface: issues in biosimilar drug development.
    Yao B; Chi E
    J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity assessment: a critical consideration for biosimilar development.
    Liu PM; Zou L; Sadhu C; Shen WD; Nock S
    Bioanalysis; 2015; 7(3):373-81. PubMed ID: 25697194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
    Ryding J; Stahl M; Ullmann M
    Bioanalysis; 2017 Sep; 9(18):1395-1406. PubMed ID: 28920451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Medicines Agency guidelines to increase the pace of biosimilar development.
    Parks L
    Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
    [No Abstract]   [Full Text] [Related]  

  • 7. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in Development Near End of Phase 3 Trials.
    Adams KT
    Manag Care; 2016 Feb; 25(2):16-8. PubMed ID: 27008829
    [No Abstract]   [Full Text] [Related]  

  • 10. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Development. Are trade secrets delaying biosimilars?
    Price WN; Rai AK
    Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
    [No Abstract]   [Full Text] [Related]  

  • 12. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar Research Proceeds in Cancer, RA, and Hep B.
    Adams KT
    Manag Care; 2016 Apr; 25(4):35-7. PubMed ID: 27265969
    [No Abstract]   [Full Text] [Related]  

  • 15. The advent of biosimilars: challenges and risks.
    Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
    Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist.
    Leach MW
    Toxicol Pathol; 2013 Jan; 41(1):128-36. PubMed ID: 22744226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2013 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2014 Jan; 13(1):5-7. PubMed ID: 24378784
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA issues guidelines for biosimilar drugs.
    Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.